Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06904378 · ClinicalTrials.gov registry record · Phase 1
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT06904378 is a Phase 1 study that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 61 participants.
The verdict
NCT06904378, a Phase 1 study, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Therefore, the investigators propose an open label phase I/II clinical trial of ONT01 with gemcitabine and nab-paclitaxel in unresectable pancreatic ductal adenocarcinoma prior to future studies incorporating anti-PD1 checkpoint immunotherapy.
Interventions
- DRUG Gemcitabine
- DRUG Nab paclitaxel
- DRUG ONT01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2026-03-25 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06904378
The ClinicalTrials.gov registry entry for NCT06904378 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT06904378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06904378 about?
NCT06904378 is a clinical study titled "ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma". The investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Therefore, the investigators propose an open label phase I/II clinical trial of ONT01 with gemcitabine and nab-p...
What is the current status of trial NCT06904378?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2026-03-25. Estimated completion is 2029-09-30.
What interventions are being tested in trial NCT06904378?
The interventions under investigation include: Gemcitabine (DRUG), Nab paclitaxel (DRUG), ONT01 (DRUG).
Who is sponsoring clinical trial NCT06904378?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.